PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 10, 2025Clinical Infectious Diseases0 citations

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

View Full Paper
ABAdarsh BhimrajYFYngve Falck‐YtterLBLindsey R. Baden

Key Points

  • The updated guidelines recommend using pemivibart for pre-exposure prophylaxis to prevent COVID-19 in at-risk patients.
  • Evidence from systematic literature reviews supports the use of vilobelimab for managing critical illness due to COVID-19.
  • The recommendations, based on the GRADE approach, emphasize the importance of tailored treatment strategies for severe or critical cases.
  • These focused updates aim to improve clinical outcomes for adults, children, and pregnant people suffering from COVID-19.

Abstract

Abstract As the first part of several focused updates to the clinical practice guideline on the treatment and management of COVID-19 in adults, children, and pregnant people, developed by the Infectious Diseases Society of America, the panel presents four new recommendations. These recommendations include pre-exposure prophylaxis for immunocompromised persons and treatment of severe or critical COVID-19. The panel’s recommendations are based upon evidence derived from systematic literature reviews and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Bhimraj et al. (2025) studied this question.

synapsesocial.com/papers/68c1ad6354b1d3bfb60e59b4https://doi.org/10.1093/cid/ciaf424
Ask AI
Helpful
Bookmark
Share
View Full Paper